FDA Approved Drugs for Vaccines

Drugs Approved in 2019

Dengvaxia (Dengue Tetravalent Vaccine, Live) ; sanofi pasteur; For the prevention of dengue disease, Approved May 2019

Jynneos (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) ; Bavarian Nordic; For the prevention of smallpox and monkeypox disease in adults, Approved September 2019

Drugs Approved in 2017

Shingrix (Zoster Vaccine Recombinant, Adjuvanted) ; GlaxoSmithKline; For the prevention of herpes zoster (shingles), Approved October 2017

Drugs Approved in 2016

Vaxchora (Cholera Vaccine, Live, Oral); PaxVax; For active immunization against Cholera, Approved June 2016

Drugs Approved in 2015

Bexsero (Meningococcal Group B Vaccine); Novartis; For the treatment of invasive meningococcal disease caused by serogroup B, Approved January 2015

Drugs Approved in 2013

Flublok (seasonal influenza vaccine); Protein Sciences; For the active immunization against influenza virus subtypes A and type B, Approved January 2013

VariZIG, Varicella Zoster Immune Globulin (Human); Cangene; For the post-exposure prophylaxis of varicella zoster (chickenpox), Approved January 2013

Drugs Approved in 2012

Flucelvax, Influenza Virus Vaccine; Novartis; For the treatment of influenza virus subtypes A and type B, Approved November 2012

Horizant (gabapentin enacarbil); GlaxoSmithKline; For the treatment of postherpetic neuralgia, Approved June 2012

Drugs Approved in 2011

Horizant (gabapentin enacarbil); GlaxoSmithKline; For the treatment of restless legs syndrome, Approved April 2011

Drugs Approved in 2010

Menveo (meningitis vaccine); Novartis; For the active immunization to prevent invasive meningococcal disease, Approved February 2010

Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine); Wyeth; For the active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae, Approved February 2010

Teflaro (ceftaroline fosamil); Cerexa; For the treatment of bacterial skin infections and bacterial pneumonia, November 2010

Drugs Approved in 2009

Hiberix (Haemophilus b Conjugate Vaccine; Tetanus Toxoid Conjugate); GlaxoSmithKline; For the prevention of invasive disease caused by Haemophilus influenzae type b., August of 2009

Drugs Approved in 2003

FluMist ( Influenza Virus Vaccine); MedImmune; For the prevention of disease caused by influenza A and B viruses, Approved June 2003

Drugs Approved in 2002

Fluzone Preservative-free; Sanofi Pasteur; Preservative free, pediatric dose, influenza virus vaccine for the immunization of infants, Approved September 2002

Neurontin (gabapentin); Pfizer; Oral treatment for the management of post-herpetic neuralgia (PHN), Approved May 2002

Pediarix Vaccine; GlaxoSmithKline; For the prevention of diphtheria, tetanus, pertussi, polio and hepatitis B in children 6 weeks to 7 years old., Approved December 2002

Drugs Approved in 2001

Avelox I.V. (moxifloxacin hydrochloride); Bayer; For adults with susceptible strains of bacterial infections, Approved November 2001

Invanz; Merck; Once-daily injectable treatment for bacterial infections, Approved November 2001

Spectracef; TAP Pharmaceuticals; Oral tablets for the treatment of mild to moderate bacterial infections, Approved August 2001

Twinrix; GlaxoSmithKline; For the prevention of hepatitis A and B, Approved May 2001

Drugs Approved in 2000

Cefazolin and Dextrose USP; B Braun Medical; Respiratory tract infections, Approved July 2000

Drugs Approved in 1999

Synercid I.V.; Rhone Poulenc Rorer; quinupristin and dalfopristin for injection, Approved September 1999

Tamiflu capsule; Roche; Oseltamivir phosphate capsule, October 27, 1999

Drugs Approved in 1997

Omnicef; Warner-Lambert; Treatment against various bacterias, Approved December 1997

Trovan; Pfizer; Treatment for bacterial infections, Approved December 1997

Zagam (sparfloxacin) tablets; Rhone Poulenc Rorer; Treatment for community-acquired pneumonia (CAP) and chronic bronchitis, Approved January 1997

Drugs Approved in 1996

Augmentin (amoxicillin/clavulanate); SmithKline Beecham; Treatment for infections involving drug-resistant bacteria, Approved February 1996

Havrix; SmithKline Beecham; Treatment for hepatitis A, Approved March 1996

Merrem I.V. (meropenem); AstraZeneca; Treatment for intra-abdominal infections and bacterial meningitis, Approved June 1996

Tripedia (Diptheria and Tetanus Toxoids and Acellular Pertussis Vaccine Absorbed); Connaught Laboratories; Treatment for whooping cough, Approved August 1996

Zosyn (sterile piperacillin sodium/tazobactam sodium); Wyeth; Treatment for hospital-acquired pneumonia, Approved May 1996